[PDF][PDF] New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
KB Hooks, J Audoux, H Fazli, S Lesjean, T Ernault… - …, 2018 - Wiley Online Library
Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the
survival of 70%‐80% of patients. However, some important challenges remain in diagnosing
high‐risk tumors and identifying relevant targetable pathways offering new therapeutic
avenues. Previously, two molecular subclasses of HB tumors have been described, C1 and
C2, with C2 being the subgroup with the poorest prognosis, a more advanced tumor stage,
and the worst overall survival rate. An associated 16‐gene signature to discriminate the two …
survival of 70%‐80% of patients. However, some important challenges remain in diagnosing
high‐risk tumors and identifying relevant targetable pathways offering new therapeutic
avenues. Previously, two molecular subclasses of HB tumors have been described, C1 and
C2, with C2 being the subgroup with the poorest prognosis, a more advanced tumor stage,
and the worst overall survival rate. An associated 16‐gene signature to discriminate the two …
[PDF][PDF] New insights into diagnosis and therapeutic options for proliferative hepatoblastoma
T Leste-lasserre, N Magendie, B Rousseau, C Danet… - researchgate.net
Surgery and cisplatin-based treatment of hepatoblastoma (HB) currently guarantee the
survival of 70-80% of patients. However, some important challenges remain in diagnosing
high risk tumors and identifying relevant targetable pathways offering new therapeutic
avenues. Previously, two molecular subclasses of hepatoblastoma tumors have been
described, namely C1 and C2; C2 being the subgroup with the poorest prognosis, a more
advanced tumor stage and the worst overall survival rate. An associated 16-gene signature …
survival of 70-80% of patients. However, some important challenges remain in diagnosing
high risk tumors and identifying relevant targetable pathways offering new therapeutic
avenues. Previously, two molecular subclasses of hepatoblastoma tumors have been
described, namely C1 and C2; C2 being the subgroup with the poorest prognosis, a more
advanced tumor stage and the worst overall survival rate. An associated 16-gene signature …